Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774193 | 1.00 | PGR (0.43) | PGRCNR2SLC6A2SLC6A4ADORA2B | |
| SCHEMBL5774187 | 1.00 | PGR (0.43) | PGRCNR2SLC6A2SLC6A4ADORA2B | |
| SCHEMBL13563364 | 0.88 | ALDH1A1 (0.42) | PGRSLC6A2SLC6A4ALDH1A1 | |
| SCHEMBL7060173 | 0.85 | TSHR (0.40) | TSHRALDH1A1 | |
| SCHEMBL7059480 | 0.85 | TSHR (0.40) | TSHRALDH1A1 | |
| SCHEMBL7059484 | 0.85 | TSHR (0.40) | TSHRALDH1A1 | |
| SCHEMBL5775377 | 0.84 | CYP1A2 (0.51) | TSHRALDH1A1 | |
| SCHEMBL5775371 | 0.84 | CYP1A2 (0.51) | TSHRALDH1A1 | |
| SCHEMBL5776233 | 0.84 | CYP1A2 (0.51) | TSHRALDH1A1 | |
| SCHEMBL13563352 | 0.84 | BRD4 (0.44) | ADORA2BTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322621-B1 | NEW BENZIMIDAZOLONE DERIVATIVES DISPLAYING AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2006-10-04 | — | — | EP | disclosed |
| EP-1322621-A1 | NEW BENZIMIDAZOLONE DERIVATIVES DISPLAYING AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-07-02 | — | — | EP | disclosed |
| US-6586435-B2 | Useful in treatment of anxiety disorders, affective disorders such as depression, psychosis and schizophrenia, Parkinson's disease | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-01 | — | — | US | disclosed |
| US-20020103208-A1 | Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors | BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA) (PL) | 2002-08-01 | — | — | US | disclosed |
| WO-2002024662-A1 | NEW BENZIMIDAZOLONE DERIVATIVES DISPLAYING AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | BOEHRINGER INGELHEIM PHARMA GMBH & KO. KG (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103208-A1 | Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors | OPRM1, HTR2C, HTR1D | PGR 378/4885CNR2 41/4885SLC6A2 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.